Coronavirus

People who experienced COVID-19 symptoms and had the virus in their saliva were more likely to report loss of taste and smell, suggesting that oral infection might underlie oral symptoms.

The companies announced they are expanding their study in children ages 6 months to 11 years old.

The president updated his goal during his press conference this afternoon.

The study also provided insight into potential differences between the immune response elicited by the two mRNA vaccines created by Pfizer and Moderna.

Tilorone, quinacrine and pyronaridines effectiveness depended on whether they were used in human-derived cell lines or monkey derived cell lines.

Serum neutralizing antibodies to SARS-CoV-2 from infection or vaccination were found to recognize and act against new variants of the virus.

Overnight, the company restated it had a 76% efficacy against symptomatic disease and is looking to file an Emergency Use Authorization (EUA) with the Food and Drug Administration (FDA).

Survivors of the disease have been found to be at an increased risk of blood clots or strokes due to a prolonged immune response caused by the virus.

More respondents with an infection reported daily burnout than those who did not have one.

People who received their vaccine were also significantly less likely to require hospitalization.

A statement hours after the company reported promising interim phase 3 data stated the Data Safety and Monitoring Board believes they included outdated data “which may have provided an incomplete view of the efficacy data.”

Levels of interferon gene activity were much lower in those with the missense mutation.

Regeneron announces results from Phase 3 trial of its monoclonal antibody treatment.

The challenges of explaining new guidance, like that for school-aged children, is so important to ensure people understand the science and reasoning behind it, but also why following it is important.

Facilities in Connecticut had an outbreak prior to vaccinating their residents, which in turn controlled the spread effectively.

Reproduction number should govern allocation of the shot, researchers say.

New polls shows confidence in AstraZeneca vaccine plummets in Europe.

The small country's emphasis on accessible testing provided more up-to-date tracking, and opportunity for research into reinfection risk.

After a year of setbacks, AZD1222 has been associated with 100% prevention of severe COVID-19 in US trial participants. Could emergency authorization come soon?

An interview on perspectives learned from a nationwide PCR test database assessment.

Patients said they would be more likely to respond to public health messaging if it came from people they know.

The Infectious Diseases Society of America (IDSA) discusses some of the new treatments show measurable impact on severe disease and death.

8% of ischemic stroke patients had atrial fibrillation, while 9% of those without stroke also had atrial fibrillation.

COVID-19 vaccine development demanded an adults-first approach. A year in, children are being invited to participate in trials in hopes of getting the pediatric population vaccinated later this year.

Machine learning is a promising and potentially powerful technique for detection and prognosis of disease.

Regardless of symptom status, the rate of participants positive for pan-immunoglobulins with neutralizing antibodies at baseline remained stable throughout 2020.

Approaches that measure the indirect effect of the virus on the host may offer complementary solutions in clinical or mass testing.

Getting kids back in classrooms is crucial, and it can be done with planning and forethought.

The US was poised in many ways to handle a public health emergency, but the attempt was largely a failure. What happened and how can we push forward?

Ultrasound is known to cause the breaking up of kidney stones and opening the lipid shell of liposome for drug delivery.